Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 15, 2019 - Issue 3
Submit an article Journal homepage
3,376
Views
31
CrossRef citations to date
0
Altmetric
Research Paper

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

James T. PetersonFoothill Family Clinic, Salt Lake City, USAView further author information
,
Helen L. StaceyDiablo Clinical Research, Walnut Creek, USAORCID Iconhttp://orcid.org/0000-0003-1919-0302View further author information
ORCID Icon,
John E. MacNairMerck & Co., Inc., Merck Research Laboratories, Kenilworth, NJ, USAView further author information
,
Jianing LiMerck & Co., Inc., Merck Research Laboratories, Kenilworth, NJ, USAView further author information
,
Jonathan S. HartzelMerck & Co., Inc., Merck Research Laboratories, Kenilworth, NJ, USAView further author information
,
Tina M. SterlingMerck & Co., Inc., Merck Research Laboratories, Kenilworth, NJ, USAView further author information
,
Patrice BennerMerck & Co., Inc., Merck Research Laboratories, Kenilworth, NJ, USAView further author information
,
Gretchen M. TammsMerck & Co., Inc., Merck Research Laboratories, Kenilworth, NJ, USAView further author information
&
Luwy K. MuseyMerck & Co., Inc., Merck Research Laboratories, Kenilworth, NJ, USACorrespondence[email protected]
View further author information
 show all
Pages 540-548 | Received 07 Jun 2018, Accepted 25 Sep 2018, Published online: 14 Nov 2018

Citations (31)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Lina Reslan, Nour Youssef, Celina F. Boutros, Aia Assaf-Casals, Danielle Fayad, Sarah Khafaja, Fata Akl, Marc Finianos, Amena A. Rizk, Rouba Shaker, Alissar Zaghlout, Mireille Lteif, Bassam El Hafi, Mohammad Bahij Moumneh, Rita Feghali, Soha Ghanem, Tamima Jisr, Gilbert Karayakoupoglou, Malak Naboulsi, Monzer Hamze, Salam Samad, Elie Khoury, Ricardo Sarraf, Marwan Osman, Elie Bou Raad, Hadi El Amin, Ibrahim Abadi, Hicham Abdo, Marwan Chedid, Fatima Chamseddine, Angelique Barakat, Mohammad Houmani, Antoine Haddad, Georges Abdel Nour, Jacques E. Mokhbat, Ziad Daoud, Mohamad El-Zaatari, Elie Salem Sokhn, Nada Ghosn, Walid Ammar, Randa Hamadeh, Ghassan M. Matar, George F. Araj & Ghassan S. Dbaibo$suffix/text()$suffix/text(). (2022) The impact of vaccination on the burden of invasive pneumococcal disease from a nationwide surveillance program in Lebanon: an unexpected increase in mortality driven by non-vaccine serotypes. Expert Review of Vaccines 21:12, pages 1905-1921.
Read now
Arijita Deb, Patrik Guggisberg, Thomas Mutschler, Kwame Owusu-Edusei, Goran Bencina, Kelly D. Johnson, Tim Ignacio, Daan A.R. Mathijssen & Venetia Qendri. (2022) Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland. Expert Review of Vaccines 21:5, pages 711-722.
Read now
Randall Severance, Howard Schwartz, Ron Dagan, Laurie Connor, Jianing Li, Alison Pedley, Jonathan Hartzel, Tina M. Sterling, Katrina M. Nolan, Gretchen M. Tamms, Luwy K. Musey & Ulrike K. Buchwald. (2022) Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU). Human Vaccines & Immunotherapeutics 18:1, pages 1-14.
Read now
Andrew Vyse, James Campling, Carole Czudek, Gillian Ellsbury, Diana Mendes, Ralf-Rene Reinert & Mary Slack. (2021) A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK. Expert Review of Vaccines 20:10, pages 1311-1325.
Read now
Viviane Maimoni Gonçalves, Kan Kaneko, Carla Solórzano, Ronan MacLoughlin, Imran Saleem & Eliane Namie Miyaji. (2019) Progress in mucosal immunization for protection against pneumococcal pneumonia. Expert Review of Vaccines 18:8, pages 781-792.
Read now

Articles from other publishers (26)

Isis Kanevsky, Naveen Surendran, Kathleen McElwee, Lanyu Lei, Wendy Watson, Michael Pride, Ingrid Scully, Hatice Karauzum, Annaliesa Anderson & Mariano Young. (2023) Comparison of pneumococcal immunogenicity elicited by the PCV13 and PCV15 vaccines in adults 18 through 49 years of age. Vaccine 41:45, pages 6625-6629.
Crossref
Miwako Kobayashi, Tamara Pilishvili, Jennifer L. Farrar, Andrew J. Leidner, Ryan Gierke, Namrata Prasad, Pedro Moro, Doug Campos-Outcalt, Rebecca L. Morgan, Sarah S. Long, Katherine A. Poehling & Adam L. Cohen. (2023) Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR. Recommendations and Reports 72:3, pages 1-39.
Crossref
Kay Choong See. (2023) Pneumococcal Vaccination in Adults: A Narrative Review of Considerations for Individualized Decision-Making. Vaccines 11:5, pages 908.
Crossref
James Z. Deng, Nathan Kuster, Ashley Drumheller, Mingxiang Lin, Frances Ansbro, Milica Grozdanovic, Rachelle Samuel & Ping Zhuang. (2023) Antibody enhanced HPLC for serotype-specific quantitation of polysaccharides in pneumococcal conjugate vaccine. npj Vaccines 8:1.
Crossref
Claudine El‐Beyrouty, Rebecca Buckler, Meghan Mitchell, Samantha Phillips & Sara Groome. (2022) Pneumococcal vaccination—A literature review and practice guideline update. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 42:9, pages 724-740.
Crossref
Saiprasad Narsingam, Jeffrey Munson & Frank Drescher. (2022) Comparative effectiveness of individual pneumococcal vaccines with dual pneumococcal vaccination in older United States Veterans. Vaccine 40:35, pages 5223-5228.
Crossref
Gurunadh R. Chichili, Ronald Smulders, Vicki Santos, Beth Cywin, Laura Kovanda, Charles Van Sant, Frank Malinoski, Shite Sebastian, George Siber & Richard Malley. (2022) Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years. Vaccine 40:31, pages 4190-4198.
Crossref
James Z. Deng, Catherine Lancaster, Michael A. Winters, Katherine M. Phillips, Ping Zhuang & Sha Ha. (2022) Multi-attribute characterization of pneumococcal conjugate vaccine by Size-exclusion chromatography coupled with UV-MALS-RI detections. Vaccine 40:10, pages 1464-1471.
Crossref
Jakub K. Simon, Nina Breinholt Staerke, Maria Hemming-Harlo, Stacey Layle, Ron Dagan, Tulin Shekar, Alison Pedley, Patricia Jumes, Gretchen Tamms, Tina Sterling, Luwy Musey & Ulrike K. Buchwald. (2022) Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE). Vaccine 40:9, pages 1342-1351.
Crossref
Miwako Kobayashi, Jennifer L. Farrar, Ryan Gierke, Amadea Britton, Lana Childs, Andrew J. Leidner, Doug Campos-Outcalt, Rebecca L. Morgan, Sarah S. Long, H. Keipp Talbot, Katherine A. Poehling & Tamara Pilishvili. (2022) Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR. Morbidity and Mortality Weekly Report 71:4, pages 109-117.
Crossref
Heather L. Platt, Jose F. Cardona, Miwa Haranaka, Howard I. Schwartz, Silvia Narejos Perez, Anthony Dowell, Chih-Jen Chang, Ron Dagan, Gretchen M. Tamms, Tina Sterling, Leslie Morgan, Yaru Shi, Alison Pedley, Luwy K. Musey & Ulrike K. Buchwald. (2022) A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine 40:1, pages 162-172.
Crossref
Karin Bergman, Tor Härnqvist, Erik Backhaus, Birger Trollfors, Mats S. Dahl, Helena Kolberg, Gunilla Ockborn, Rune Andersson, Johanna Karlsson, Åsa Mellgren & Susann Skovbjerg. (2021) Invasive pneumococcal disease in persons with predisposing factors is dominated by non-vaccine serotypes in Southwest Sweden. BMC Infectious Diseases 21:1.
Crossref
Giuliana S. Oliveira, Maria Leonor S. Oliveira, Eliane N. Miyaji & Tasson C. Rodrigues. (2021) Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies. Vaccines 9:11, pages 1338.
Crossref
Joon-Young Song, Chih-Jen Chang, Charles Andrews, Javier Diez-Domingo, Myoung-don Oh, Ron Dagan, Jonathan Hartzel, Alison Pedley, Jianing Li, Tina Sterling, Gretchen Tamms, Joseph A. Chiarappa, Jeannine Lutkiewicz, Luwy Musey, Yingmei Tu & Ulrike K. Buchwald. (2021) Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH). Vaccine 39:43, pages 6422-6436.
Crossref
Catarina Silva-Costa, Joana Gomes-Silva, Lúcia Prados, Mário Ramirez & José Melo-Cristino. (2021) Pediatric Invasive Pneumococcal Disease Three Years after PCV13 Introduction in the National Immunization Plan—The Continued Importance of Serotype 3. Microorganisms 9:7, pages 1428.
Crossref
Debra McGuinness, Robin M. Kaufhold, Patrick M. McHugh, Michael A Winters, William J. Smith, Cecilia Giovarelli, Jian He, Yuhua Zhang, Luwy Musey & Julie M. Skinner. (2021) Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice. Vaccine 39:30, pages 4231-4237.
Crossref
Kenneth J. Smith, Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner & Richard K. Zimmerman. (2021) Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. Seniors. American Journal of Preventive Medicine 61:1, pages 28-36.
Crossref
Catarina Silva-Costa, Joana Gomes-Silva, Inês Teodoro, Mário Ramirez & José Melo-Cristino. (2021) Invasive Pneumococcal Disease in Adults in Portugal: The Importance of Serotypes 8 and 3 (2015–2018). Microorganisms 9:5, pages 1016.
Crossref
Jing Zhao, Gang Hu, Yi Huang, Yingchun Huang, Xin Wei & Jianyou Shi. (2021) Polysaccharide conjugate vaccine: A kind of vaccine with great development potential. Chinese Chemical Letters 32:4, pages 1331-1340.
Crossref
Andrew Vyse, James Campling, Carole Czudek, Gillian Ellsbury & Mary Slack. (2020) The proportion of contemporary invasive pneumococcal disease and pneumococcal pneumonia in UK adults reflected by serotypes included in the 13-valent pneumococcal conjugate vaccine and next generation higher valency pneumococcal conjugate vaccines in development. Vaccine 38:51, pages 8068-8070.
Crossref
Heather L. Platt, David Greenberg, Bruce Tapiero, Robert A. Clifford, Nicola P. Klein, David C. HurleyTulin Shekar, Jianing Li, Kim Hurtado, Shu-Chih Su, Katrina M. Nolan, Camilo J. Acosta, Richard D. McFetridge, Kara Bickham & Luwy K. Musey. (2020) A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. Pediatric Infectious Disease Journal 39:8, pages 763-770.
Crossref
Regie Lyn P. Santos-Cortez, Mahmood F. Bhutta, Joshua P. Earl, Lena Hafrén, Michael Jennings, Joshua C. Mell, Michael E. Pichichero, Allen F. Ryan, Hilda Tateossian & Garth D. Ehrlich. (2020) Panel 3: Genomics, precision medicine and targeted therapies. International Journal of Pediatric Otorhinolaryngology 130, pages 109835.
Crossref
Charles Feldman & Ronald Anderson. (2020) Recent advances in the epidemiology and prevention of Streptococcus pneumoniae infections. F1000Research 9, pages 338.
Crossref
Jinfu Xie, Yuhua Zhang, Ivette Caro-Aguilar, Lani Indrawati, William J. Smith, Cecilia Giovarelli, Michael A. Winters, John MacNair, Jian He, Chitrananda Abeygunawardana, Luwy MuseyMichael Kosinski & Julie M. Skinner. (2020) Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human Infants. Pediatric Infectious Disease Journal 39:1, pages 70-77.
Crossref
Florian Thalhammer. (2019) Empfohlene Impfungen bei Lungenkranken. Pneumo News 11:5, pages 35-41.
Crossref
Michael P. Veve & Vasilios Athans. 2019. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions 351 372 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.